| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 61 | 2023 | 5662 | 5.640 |
Why?
|
| Carcinoma, Merkel Cell | 7 | 2023 | 299 | 3.710 |
Why?
|
| Melanoma | 36 | 2023 | 5462 | 3.290 |
Why?
|
| Sweat Gland Neoplasms | 9 | 2013 | 108 | 3.010 |
Why?
|
| Polyomavirus Infections | 4 | 2023 | 196 | 2.830 |
Why?
|
| Skin | 19 | 2022 | 4353 | 2.560 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 6 | 2017 | 25 | 2.550 |
Why?
|
| Immunohistochemistry | 59 | 2023 | 11363 | 2.480 |
Why?
|
| Proto-Oncogene Proteins B-raf | 15 | 2023 | 2028 | 1.830 |
Why?
|
| Tumor Virus Infections | 4 | 2023 | 451 | 1.760 |
Why?
|
| Nevus, Pigmented | 8 | 2015 | 219 | 1.480 |
Why?
|
| Uveal Neoplasms | 2 | 2023 | 310 | 1.440 |
Why?
|
| Ki-67 Antigen | 10 | 2016 | 644 | 1.380 |
Why?
|
| Carcinoma, Squamous Cell | 14 | 2023 | 4029 | 1.340 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2020 | 545 | 1.210 |
Why?
|
| Drug Eruptions | 4 | 2017 | 295 | 1.210 |
Why?
|
| Vulvar Neoplasms | 3 | 2018 | 272 | 1.200 |
Why?
|
| Apocrine Glands | 3 | 2012 | 31 | 1.170 |
Why?
|
| Carcinoma | 7 | 2013 | 2374 | 1.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 1038 | 1.100 |
Why?
|
| Sebaceous Gland Neoplasms | 3 | 2013 | 39 | 1.080 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2023 | 449 | 1.040 |
Why?
|
| Diagnosis, Differential | 38 | 2021 | 12958 | 0.980 |
Why?
|
| Facial Neoplasms | 3 | 2012 | 121 | 0.980 |
Why?
|
| Eccrine Porocarcinoma | 3 | 2013 | 15 | 0.970 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2021 | 109 | 0.920 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 4 | 2022 | 41 | 0.890 |
Why?
|
| Alopecia | 4 | 2019 | 381 | 0.860 |
Why?
|
| Hair Follicle | 4 | 2015 | 209 | 0.830 |
Why?
|
| Syphilis | 3 | 2019 | 226 | 0.830 |
Why?
|
| Pilomatrixoma | 2 | 2013 | 23 | 0.820 |
Why?
|
| Adenoma, Sweat Gland | 2 | 2013 | 18 | 0.810 |
Why?
|
| Eccrine Glands | 2 | 2012 | 45 | 0.800 |
Why?
|
| GATA3 Transcription Factor | 3 | 2017 | 157 | 0.790 |
Why?
|
| Merkel Cells | 1 | 2020 | 25 | 0.750 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2020 | 64 | 0.750 |
Why?
|
| Panniculitis | 1 | 2020 | 44 | 0.740 |
Why?
|
| Carcinoma, Skin Appendage | 2 | 2011 | 6 | 0.730 |
Why?
|
| Biopsy | 24 | 2021 | 6756 | 0.730 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 106 | 0.730 |
Why?
|
| Skin Diseases, Vesiculobullous | 4 | 2013 | 85 | 0.720 |
Why?
|
| Vulvar Diseases | 2 | 2014 | 61 | 0.670 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 325 | 0.670 |
Why?
|
| Precancerous Conditions | 3 | 2023 | 971 | 0.670 |
Why?
|
| Aged, 80 and over | 43 | 2021 | 57683 | 0.660 |
Why?
|
| Carcinoma in Situ | 4 | 2019 | 802 | 0.660 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2016 | 2842 | 0.660 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 5 | 2014 | 67 | 0.650 |
Why?
|
| Keratin-15 | 4 | 2010 | 22 | 0.650 |
Why?
|
| Behcet Syndrome | 2 | 2019 | 84 | 0.640 |
Why?
|
| Oral Ulcer | 2 | 2019 | 96 | 0.640 |
Why?
|
| Mutation | 18 | 2023 | 29717 | 0.640 |
Why?
|
| Intermediate Filament Proteins | 5 | 2012 | 269 | 0.630 |
Why?
|
| DNA Mutational Analysis | 10 | 2023 | 4187 | 0.630 |
Why?
|
| Humans | 181 | 2023 | 742088 | 0.630 |
Why?
|
| Skin Diseases | 6 | 2015 | 1065 | 0.620 |
Why?
|
| Middle Aged | 82 | 2022 | 213127 | 0.600 |
Why?
|
| Membrane Proteins | 6 | 2021 | 7873 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2017 | 78 | 0.580 |
Why?
|
| Adenocarcinoma | 9 | 2017 | 6347 | 0.580 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2019 | 234 | 0.570 |
Why?
|
| Mucous Membrane | 1 | 2020 | 670 | 0.560 |
Why?
|
| GTP Phosphohydrolases | 2 | 2019 | 508 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-kit | 7 | 2021 | 774 | 0.520 |
Why?
|
| Melanocytes | 7 | 2023 | 515 | 0.520 |
Why?
|
| Arthritis | 1 | 2020 | 658 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2723 | 0.510 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 602 | 0.510 |
Why?
|
| Cadherins | 3 | 2023 | 906 | 0.500 |
Why?
|
| Male | 96 | 2022 | 349538 | 0.500 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2016 | 221 | 0.500 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6534 | 0.490 |
Why?
|
| von Hippel-Lindau Disease | 4 | 2003 | 152 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 7 | 2014 | 9274 | 0.490 |
Why?
|
| Cell Nucleus | 3 | 2020 | 2968 | 0.490 |
Why?
|
| Skin Diseases, Papulosquamous | 2 | 2006 | 18 | 0.490 |
Why?
|
| Aged | 55 | 2021 | 162944 | 0.480 |
Why?
|
| Female | 100 | 2022 | 379592 | 0.480 |
Why?
|
| Vulva | 2 | 2013 | 87 | 0.480 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2014 | 177 | 0.480 |
Why?
|
| Avitaminosis | 1 | 2014 | 34 | 0.480 |
Why?
|
| In Situ Hybridization | 3 | 2017 | 1950 | 0.470 |
Why?
|
| Nerve Tissue Proteins | 9 | 2022 | 4465 | 0.470 |
Why?
|
| Cicatrix | 2 | 2010 | 761 | 0.470 |
Why?
|
| Adrenal Cortex | 1 | 2014 | 139 | 0.470 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 2007 | 20 | 0.460 |
Why?
|
| Adult | 73 | 2021 | 213712 | 0.460 |
Why?
|
| Nevus, Blue | 2 | 2011 | 38 | 0.460 |
Why?
|
| Pancreatitis | 1 | 2020 | 1090 | 0.460 |
Why?
|
| Paget Disease, Extramammary | 1 | 2013 | 43 | 0.450 |
Why?
|
| Lip | 1 | 2015 | 195 | 0.450 |
Why?
|
| Eye Diseases | 1 | 2019 | 670 | 0.450 |
Why?
|
| Nevus | 2 | 2005 | 204 | 0.450 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2013 | 21 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2021 | 8425 | 0.450 |
Why?
|
| Pemphigus | 1 | 2013 | 103 | 0.440 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 1837 | 0.440 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 4438 | 0.440 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 1060 | 0.430 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2023 | 2455 | 0.430 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3691 | 0.430 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2012 | 19 | 0.430 |
Why?
|
| Dermatitis | 1 | 2014 | 197 | 0.430 |
Why?
|
| Carcinosarcoma | 1 | 2013 | 108 | 0.430 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2002 | 49 | 0.420 |
Why?
|
| Exanthema | 5 | 2019 | 488 | 0.420 |
Why?
|
| Predictive Value of Tests | 14 | 2020 | 15056 | 0.420 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2023 | 4553 | 0.410 |
Why?
|
| Tuberculosis, Cutaneous | 2 | 2018 | 17 | 0.410 |
Why?
|
| Prognosis | 15 | 2023 | 29010 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 3 | 2021 | 2712 | 0.410 |
Why?
|
| Poland | 2 | 2023 | 184 | 0.400 |
Why?
|
| Calciphylaxis | 1 | 2013 | 122 | 0.400 |
Why?
|
| Vulvitis | 1 | 2010 | 8 | 0.390 |
Why?
|
| Laryngeal Neoplasms | 2 | 2005 | 512 | 0.380 |
Why?
|
| Rhabdomyolysis | 1 | 2012 | 150 | 0.380 |
Why?
|
| Vision Disorders | 2 | 2019 | 1057 | 0.380 |
Why?
|
| Up-Regulation | 1 | 2020 | 4211 | 0.380 |
Why?
|
| Papillomaviridae | 1 | 2017 | 1118 | 0.380 |
Why?
|
| Acrospiroma | 1 | 2010 | 13 | 0.380 |
Why?
|
| Carcinoma, Small Cell | 2 | 2004 | 420 | 0.380 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2022 | 2099 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2016 | 2948 | 0.370 |
Why?
|
| Scalp Dermatoses | 2 | 2019 | 40 | 0.370 |
Why?
|
| Ulcer | 3 | 2020 | 209 | 0.370 |
Why?
|
| Skin Ulcer | 2 | 2021 | 118 | 0.370 |
Why?
|
| Immunoenzyme Techniques | 10 | 2016 | 1799 | 0.360 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2009 | 15 | 0.350 |
Why?
|
| Hamartoma | 1 | 2011 | 234 | 0.350 |
Why?
|
| Hemangioblastoma | 2 | 2014 | 70 | 0.340 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 4839 | 0.340 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2006 | 58 | 0.330 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 1581 | 0.330 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 363 | 0.330 |
Why?
|
| Pituitary Neoplasms | 2 | 2014 | 1340 | 0.330 |
Why?
|
| Phosphoproteins | 2 | 2019 | 2440 | 0.330 |
Why?
|
| Stem Cells | 3 | 2011 | 3563 | 0.330 |
Why?
|
| Receptors, Nerve Growth Factor | 3 | 2021 | 200 | 0.320 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2017 | 2638 | 0.320 |
Why?
|
| Dermatofibrosarcoma | 3 | 2007 | 62 | 0.320 |
Why?
|
| Treponema pallidum | 2 | 2006 | 40 | 0.320 |
Why?
|
| Histones | 3 | 2009 | 2597 | 0.320 |
Why?
|
| RNA, Viral | 1 | 2017 | 2899 | 0.320 |
Why?
|
| Herpesvirus 6, Human | 2 | 1999 | 95 | 0.320 |
Why?
|
| Urticaria | 3 | 2022 | 150 | 0.320 |
Why?
|
| Papillomavirus Infections | 2 | 2017 | 1585 | 0.320 |
Why?
|
| Antigens, CD34 | 3 | 2009 | 657 | 0.310 |
Why?
|
| Keratins | 6 | 2012 | 515 | 0.310 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 992 | 0.310 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2023 | 100 | 0.300 |
Why?
|
| Folliculitis | 2 | 2019 | 28 | 0.300 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2023 | 140 | 0.300 |
Why?
|
| Hydroxychloroquine | 2 | 2021 | 408 | 0.300 |
Why?
|
| Receptor, erbB-2 | 5 | 2013 | 2410 | 0.290 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2023 | 713 | 0.290 |
Why?
|
| Ear, External | 2 | 2004 | 160 | 0.290 |
Why?
|
| Syphilis, Cutaneous | 1 | 2006 | 5 | 0.290 |
Why?
|
| Young Adult | 18 | 2021 | 56350 | 0.280 |
Why?
|
| Granular Cell Tumor | 1 | 2007 | 51 | 0.280 |
Why?
|
| Follicular Cyst | 1 | 2006 | 2 | 0.280 |
Why?
|
| Inhibins | 3 | 2003 | 211 | 0.280 |
Why?
|
| Schistosoma haematobium | 1 | 2006 | 11 | 0.280 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2023 | 1683 | 0.280 |
Why?
|
| Schistosomiasis haematobia | 1 | 2006 | 15 | 0.280 |
Why?
|
| Penile Neoplasms | 2 | 2019 | 159 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 8 | 2017 | 6171 | 0.270 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2006 | 31 | 0.270 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2006 | 63 | 0.270 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 4147 | 0.270 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 5851 | 0.260 |
Why?
|
| Epidermal Cyst | 1 | 2006 | 62 | 0.260 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2023 | 3585 | 0.260 |
Why?
|
| Dermatomycoses | 1 | 2005 | 45 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 7 | 2017 | 3612 | 0.260 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2005 | 50 | 0.260 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 890 | 0.260 |
Why?
|
| Carcinoma, Verrucous | 1 | 2005 | 23 | 0.260 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2005 | 111 | 0.260 |
Why?
|
| SOXE Transcription Factors | 2 | 2023 | 57 | 0.250 |
Why?
|
| Ampulla of Vater | 1 | 2005 | 141 | 0.250 |
Why?
|
| Ascomycota | 1 | 2005 | 82 | 0.250 |
Why?
|
| Tuberculosis, Miliary | 1 | 2004 | 13 | 0.250 |
Why?
|
| Miliaria | 1 | 2004 | 6 | 0.250 |
Why?
|
| Ichthyosiform Erythroderma, Congenital | 1 | 2004 | 7 | 0.240 |
Why?
|
| Chondrodysplasia Punctata | 1 | 2004 | 10 | 0.240 |
Why?
|
| Keratin-6 | 2 | 2014 | 18 | 0.240 |
Why?
|
| Caspase 3 | 1 | 2007 | 759 | 0.240 |
Why?
|
| Dysplastic Nevus Syndrome | 3 | 2014 | 63 | 0.240 |
Why?
|
| Necrosis | 3 | 2023 | 1643 | 0.240 |
Why?
|
| Keratin-5 | 2 | 2014 | 46 | 0.240 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 2986 | 0.240 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2007 | 171 | 0.240 |
Why?
|
| DNA, Neoplasm | 3 | 2011 | 1758 | 0.240 |
Why?
|
| Survival Analysis | 5 | 2020 | 10248 | 0.240 |
Why?
|
| Testicular Diseases | 1 | 2004 | 71 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 13655 | 0.240 |
Why?
|
| Immunocompromised Host | 4 | 2020 | 847 | 0.240 |
Why?
|
| Trisomy | 2 | 2010 | 266 | 0.240 |
Why?
|
| Esophageal Neoplasms | 2 | 2005 | 1581 | 0.230 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2004 | 600 | 0.230 |
Why?
|
| Giant Cell Tumors | 2 | 2007 | 99 | 0.230 |
Why?
|
| Carcinoid Tumor | 2 | 2002 | 235 | 0.230 |
Why?
|
| Biological Products | 1 | 2012 | 856 | 0.230 |
Why?
|
| Cecal Neoplasms | 1 | 2003 | 29 | 0.230 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2004 | 83 | 0.230 |
Why?
|
| Endolymphatic Sac | 1 | 2003 | 50 | 0.220 |
Why?
|
| Cell Proliferation | 5 | 2015 | 10472 | 0.220 |
Why?
|
| Ear Diseases | 1 | 2004 | 169 | 0.220 |
Why?
|
| Ear Neoplasms | 1 | 2003 | 117 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1376 | 0.210 |
Why?
|
| Scalp | 1 | 2005 | 380 | 0.210 |
Why?
|
| Biopsy, Needle | 5 | 2018 | 1640 | 0.210 |
Why?
|
| Chromosomes, Human, X | 1 | 2004 | 296 | 0.210 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2022 | 37 | 0.210 |
Why?
|
| Forkhead Transcription Factors | 2 | 2021 | 1613 | 0.210 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2006 | 385 | 0.210 |
Why?
|
| Glioma | 2 | 2015 | 3388 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-ret | 4 | 2016 | 220 | 0.210 |
Why?
|
| Ossification, Heterotopic | 1 | 2004 | 239 | 0.210 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2021 | 35 | 0.210 |
Why?
|
| Glucocorticoids | 4 | 2019 | 2107 | 0.200 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2001 | 22 | 0.200 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2002 | 88 | 0.200 |
Why?
|
| Gene Amplification | 2 | 2010 | 1062 | 0.200 |
Why?
|
| Loss of Heterozygosity | 3 | 2016 | 678 | 0.200 |
Why?
|
| Silicone Gels | 1 | 2021 | 39 | 0.200 |
Why?
|
| Sensitivity and Specificity | 7 | 2014 | 14720 | 0.200 |
Why?
|
| Neoplasms | 5 | 2022 | 21596 | 0.200 |
Why?
|
| Leiomyosarcoma | 2 | 2003 | 477 | 0.200 |
Why?
|
| Adolescent | 20 | 2021 | 85649 | 0.200 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2021 | 45 | 0.190 |
Why?
|
| Retrospective Studies | 20 | 2021 | 77098 | 0.190 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 3769 | 0.190 |
Why?
|
| Buttocks | 1 | 2021 | 110 | 0.190 |
Why?
|
| Thiolester Hydrolases | 1 | 2001 | 86 | 0.190 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2002 | 143 | 0.190 |
Why?
|
| Lichen Planus | 1 | 2021 | 57 | 0.190 |
Why?
|
| Telomerase | 2 | 2016 | 729 | 0.190 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2002 | 162 | 0.190 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2003 | 199 | 0.190 |
Why?
|
| Medical Tourism | 1 | 2021 | 57 | 0.190 |
Why?
|
| Herpesviridae Infections | 2 | 1999 | 277 | 0.190 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 654 | 0.190 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 204 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 364 | 0.180 |
Why?
|
| Herpesvirus 2, Human | 1 | 2021 | 185 | 0.180 |
Why?
|
| Mucins | 1 | 2003 | 564 | 0.180 |
Why?
|
| Dermis | 1 | 2021 | 207 | 0.180 |
Why?
|
| Claudins | 1 | 2020 | 111 | 0.180 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2001 | 190 | 0.180 |
Why?
|
| Honey | 1 | 2019 | 11 | 0.180 |
Why?
|
| Genes, erbB-2 | 1 | 2000 | 162 | 0.180 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 223 | 0.180 |
Why?
|
| Iritis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Carrier Proteins | 1 | 2013 | 5019 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 1335 | 0.170 |
Why?
|
| Lymphatic Metastasis | 4 | 2020 | 2906 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2007 | 1361 | 0.170 |
Why?
|
| Breast Neoplasms | 5 | 2013 | 20774 | 0.170 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2003 | 484 | 0.170 |
Why?
|
| Gene Fusion | 1 | 2022 | 371 | 0.170 |
Why?
|
| Stromal Cells | 2 | 2021 | 1353 | 0.170 |
Why?
|
| Taiwan | 1 | 2020 | 496 | 0.170 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2019 | 28 | 0.170 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 1792 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 792 | 0.170 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2019 | 75 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2002 | 382 | 0.170 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1999 | 114 | 0.170 |
Why?
|
| Epitopes | 3 | 2021 | 2569 | 0.170 |
Why?
|
| Tissue Fixation | 2 | 2017 | 241 | 0.170 |
Why?
|
| Parvovirus B19, Human | 1 | 1998 | 38 | 0.160 |
Why?
|
| Herpesviridae | 1 | 1999 | 109 | 0.160 |
Why?
|
| Clinical Chemistry Tests | 1 | 1998 | 61 | 0.160 |
Why?
|
| Lymph Nodes | 5 | 2015 | 3465 | 0.160 |
Why?
|
| Pigmentation | 1 | 2019 | 148 | 0.160 |
Why?
|
| Mesenteric Arteries | 1 | 1998 | 183 | 0.160 |
Why?
|
| Scleritis | 1 | 2019 | 100 | 0.160 |
Why?
|
| Hedgehog Proteins | 1 | 2023 | 781 | 0.160 |
Why?
|
| Herpes Simplex | 1 | 2021 | 466 | 0.160 |
Why?
|
| Hospitals, General | 2 | 2013 | 749 | 0.160 |
Why?
|
| Syndrome | 2 | 2020 | 3248 | 0.160 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2001 | 297 | 0.150 |
Why?
|
| Fundus Oculi | 1 | 2019 | 472 | 0.150 |
Why?
|
| Vascular Neoplasms | 1 | 2019 | 175 | 0.150 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 13019 | 0.150 |
Why?
|
| Anetoderma | 1 | 2017 | 1 | 0.150 |
Why?
|
| DNA Probes, HPV | 1 | 2017 | 21 | 0.150 |
Why?
|
| Sulfasalazine | 1 | 2017 | 79 | 0.150 |
Why?
|
| Kidney Diseases | 2 | 2019 | 2145 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2003 | 3123 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 2 | 2002 | 1040 | 0.150 |
Why?
|
| beta Catenin | 2 | 2020 | 1058 | 0.150 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2017 | 62 | 0.150 |
Why?
|
| RNA Probes | 1 | 2017 | 113 | 0.150 |
Why?
|
| Carcinoma, Papillary | 1 | 2002 | 781 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 1 | 2002 | 567 | 0.150 |
Why?
|
| Fixatives | 1 | 2017 | 94 | 0.150 |
Why?
|
| Radiography, Abdominal | 1 | 2020 | 537 | 0.150 |
Why?
|
| Pathology, Clinical | 2 | 2012 | 368 | 0.150 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 740 | 0.150 |
Why?
|
| Death, Sudden | 1 | 1999 | 298 | 0.150 |
Why?
|
| Blood Donors | 1 | 1999 | 355 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 694 | 0.140 |
Why?
|
| Mucinosis, Follicular | 1 | 2016 | 8 | 0.140 |
Why?
|
| S100 Proteins | 3 | 2002 | 259 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 12242 | 0.140 |
Why?
|
| Fetal Death | 1 | 1999 | 447 | 0.140 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 435 | 0.140 |
Why?
|
| Transcription Factors | 4 | 2023 | 12164 | 0.140 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 101 | 0.140 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2012 | 347 | 0.140 |
Why?
|
| Blood | 1 | 1999 | 598 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1052 | 0.140 |
Why?
|
| Dermatology | 3 | 2012 | 870 | 0.140 |
Why?
|
| Bone Marrow Diseases | 1 | 1998 | 230 | 0.140 |
Why?
|
| Albumins | 1 | 1999 | 568 | 0.140 |
Why?
|
| Fluorescent Antibody Technique, Direct | 2 | 2018 | 69 | 0.140 |
Why?
|
| Mutation, Missense | 3 | 2014 | 2556 | 0.140 |
Why?
|
| Serum Albumin | 1 | 1999 | 674 | 0.140 |
Why?
|
| Genes, p16 | 1 | 2016 | 157 | 0.140 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 712 | 0.140 |
Why?
|
| Mongolian Spot | 1 | 2015 | 3 | 0.140 |
Why?
|
| Gangliosidosis, GM1 | 1 | 2015 | 10 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 12344 | 0.140 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 299 | 0.140 |
Why?
|
| Herpesvirus 1, Human | 1 | 2021 | 742 | 0.140 |
Why?
|
| Facial Dermatoses | 1 | 2016 | 87 | 0.130 |
Why?
|
| ras Proteins | 2 | 2011 | 1060 | 0.130 |
Why?
|
| Mesoderm | 1 | 1999 | 686 | 0.130 |
Why?
|
| Kidney Neoplasms | 2 | 2003 | 4229 | 0.130 |
Why?
|
| Hypertriglyceridemia | 1 | 1998 | 293 | 0.130 |
Why?
|
| Formaldehyde | 1 | 2017 | 353 | 0.130 |
Why?
|
| Embolism, Cholesterol | 1 | 2015 | 34 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 438 | 0.130 |
Why?
|
| Nephrotic Syndrome | 1 | 1999 | 389 | 0.130 |
Why?
|
| X Chromosome | 1 | 1999 | 815 | 0.130 |
Why?
|
| Sweet Syndrome | 2 | 2012 | 47 | 0.130 |
Why?
|
| Albuminuria | 1 | 1999 | 683 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 1 | 1998 | 460 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 2022 | 1407 | 0.130 |
Why?
|
| Axonemal Dyneins | 1 | 2014 | 24 | 0.130 |
Why?
|
| Calcinosis | 1 | 2004 | 1497 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2003 | 895 | 0.130 |
Why?
|
| Immunodominant Epitopes | 1 | 2016 | 267 | 0.130 |
Why?
|
| Colonic Neoplasms | 2 | 2005 | 2542 | 0.130 |
Why?
|
| Genital Diseases, Male | 1 | 2015 | 83 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1659 | 0.120 |
Why?
|
| Neurofibromin 1 | 1 | 2016 | 196 | 0.120 |
Why?
|
| Proto-Oncogenes | 1 | 2015 | 321 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3471 | 0.120 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2016 | 311 | 0.120 |
Why?
|
| Fibroma | 2 | 2007 | 212 | 0.120 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 2014 | 24 | 0.120 |
Why?
|
| Cytomegalovirus | 1 | 1998 | 730 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 2020 | 1059 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2001 | 1101 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 522 | 0.120 |
Why?
|
| Pancreas | 1 | 2020 | 1684 | 0.120 |
Why?
|
| Anthraquinones | 1 | 2013 | 35 | 0.120 |
Why?
|
| Lasers | 1 | 2018 | 952 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 1377 | 0.110 |
Why?
|
| Vitamin A Deficiency | 1 | 2014 | 101 | 0.110 |
Why?
|
| Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 987 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 247 | 0.110 |
Why?
|
| Keratin-17 | 1 | 2013 | 26 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 290 | 0.110 |
Why?
|
| Fluorouracil | 1 | 2018 | 1615 | 0.110 |
Why?
|
| Mohs Surgery | 1 | 2015 | 197 | 0.110 |
Why?
|
| Cocaine | 1 | 1998 | 1008 | 0.110 |
Why?
|
| Child | 12 | 2016 | 77478 | 0.110 |
Why?
|
| Actins | 1 | 2020 | 2120 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 701 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2013 | 1057 | 0.110 |
Why?
|
| Cheek | 1 | 2012 | 63 | 0.110 |
Why?
|
| Adenoma | 1 | 2003 | 2168 | 0.110 |
Why?
|
| Laminin | 1 | 2014 | 418 | 0.100 |
Why?
|
| Intestine, Small | 1 | 1998 | 1243 | 0.100 |
Why?
|
| Lymphoma | 1 | 2021 | 1873 | 0.100 |
Why?
|
| Pemphigoid, Bullous | 1 | 2014 | 108 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 281 | 0.100 |
Why?
|
| Hair Color | 1 | 2012 | 136 | 0.100 |
Why?
|
| Antibody Specificity | 1 | 2014 | 1094 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 1538 | 0.100 |
Why?
|
| Cholesterol, HDL | 1 | 1998 | 1813 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21719 | 0.100 |
Why?
|
| Cisplatin | 1 | 2018 | 1637 | 0.100 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 343 | 0.100 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2011 | 31 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2012 | 2938 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2013 | 500 | 0.100 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 494 | 0.100 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2012 | 79 | 0.100 |
Why?
|
| Peripheral Nerves | 1 | 2015 | 474 | 0.100 |
Why?
|
| Infant | 8 | 2016 | 35070 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 1999 | 1416 | 0.100 |
Why?
|
| Chromogranins | 2 | 2002 | 163 | 0.100 |
Why?
|
| Headache | 1 | 2019 | 1219 | 0.100 |
Why?
|
| Arthritis, Reactive | 1 | 2010 | 19 | 0.100 |
Why?
|
| Craniopharyngioma | 1 | 2014 | 281 | 0.100 |
Why?
|
| Massachusetts | 3 | 2013 | 8662 | 0.100 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2012 | 75 | 0.100 |
Why?
|
| Cilia | 1 | 2014 | 463 | 0.100 |
Why?
|
| Coloring Agents | 1 | 2013 | 565 | 0.090 |
Why?
|
| Staining and Labeling | 2 | 2013 | 1099 | 0.090 |
Why?
|
| Citalopram | 1 | 2013 | 404 | 0.090 |
Why?
|
| Polymorphism, Genetic | 3 | 2016 | 4328 | 0.090 |
Why?
|
| Skin Pigmentation | 1 | 2012 | 281 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 2 | 2002 | 183 | 0.090 |
Why?
|
| Microscopy | 1 | 2015 | 903 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 11001 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2010 | 1811 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39004 | 0.090 |
Why?
|
| Erythema | 2 | 2018 | 254 | 0.090 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 870 | 0.090 |
Why?
|
| Sex Factors | 2 | 2021 | 10392 | 0.090 |
Why?
|
| Linear Models | 1 | 2020 | 5948 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 4801 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 585 | 0.090 |
Why?
|
| Ischemia | 1 | 1998 | 1911 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 577 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 657 | 0.090 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 19862 | 0.090 |
Why?
|
| Pathology, Surgical | 1 | 2010 | 155 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2015 | 604 | 0.080 |
Why?
|
| Blister | 1 | 2009 | 85 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 1097 | 0.080 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 1983 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 622 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2021 | 2224 | 0.080 |
Why?
|
| Neurofibroma | 1 | 2009 | 106 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 9185 | 0.080 |
Why?
|
| Disease Progression | 4 | 2023 | 13256 | 0.080 |
Why?
|
| Child, Preschool | 7 | 2016 | 40955 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2020 | 11470 | 0.080 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 2861 | 0.080 |
Why?
|
| Microscopy, Electron | 2 | 2002 | 2645 | 0.080 |
Why?
|
| Genes, ras | 1 | 2011 | 691 | 0.080 |
Why?
|
| Subcutaneous Tissue | 2 | 2012 | 135 | 0.080 |
Why?
|
| Apolipoproteins D | 1 | 2007 | 14 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3510 | 0.080 |
Why?
|
| Monophenol Monooxygenase | 2 | 2012 | 69 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 1248 | 0.080 |
Why?
|
| HIV Infections | 3 | 2006 | 16678 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2012 | 1059 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2014 | 1849 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2276 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 1786 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 933 | 0.070 |
Why?
|
| Psoriasis | 2 | 2005 | 898 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2000 | 1676 | 0.070 |
Why?
|
| Mitosis | 2 | 2015 | 1208 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4664 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2010 | 2924 | 0.070 |
Why?
|
| Age Factors | 2 | 2021 | 18355 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2019 | 40450 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6891 | 0.070 |
Why?
|
| Xanthomatosis | 1 | 2006 | 32 | 0.070 |
Why?
|
| Keratin-7 | 2 | 2002 | 57 | 0.070 |
Why?
|
| Argyria | 1 | 2005 | 2 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2011 | 2295 | 0.070 |
Why?
|
| Axilla | 2 | 2014 | 588 | 0.070 |
Why?
|
| Brain Neoplasms | 3 | 2015 | 8829 | 0.070 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2005 | 46 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2013 | 987 | 0.070 |
Why?
|
| Itraconazole | 1 | 2005 | 42 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2014 | 2036 | 0.070 |
Why?
|
| Age Distribution | 1 | 2011 | 2900 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2021 | 62966 | 0.060 |
Why?
|
| Antibodies, Antinuclear | 1 | 2006 | 326 | 0.060 |
Why?
|
| Silver Staining | 1 | 2004 | 64 | 0.060 |
Why?
|
| Fluconazole | 1 | 2005 | 146 | 0.060 |
Why?
|
| Verapamil | 1 | 2005 | 244 | 0.060 |
Why?
|
| Cryotherapy | 1 | 2005 | 154 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1575 | 0.060 |
Why?
|
| West Nile Fever | 1 | 2004 | 78 | 0.060 |
Why?
|
| Membrane Microdomains | 1 | 2005 | 202 | 0.060 |
Why?
|
| Sunlight | 1 | 2006 | 325 | 0.060 |
Why?
|
| Prednisolone | 1 | 2005 | 333 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 1331 | 0.060 |
Why?
|
| Kidney | 1 | 2019 | 7167 | 0.060 |
Why?
|
| Cysts | 1 | 2009 | 676 | 0.060 |
Why?
|
| Leprosy | 1 | 2004 | 127 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 1420 | 0.060 |
Why?
|
| Communicable Diseases | 1 | 2012 | 878 | 0.060 |
Why?
|
| Penicillins | 1 | 2006 | 378 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2001 | 5249 | 0.060 |
Why?
|
| Calcitriol | 1 | 2005 | 298 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5095 | 0.060 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2003 | 135 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8621 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2005 | 345 | 0.050 |
Why?
|
| Pancreatic Polypeptide | 1 | 2002 | 34 | 0.050 |
Why?
|
| Gastrins | 1 | 2002 | 81 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 20086 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 15530 | 0.050 |
Why?
|
| Carcinoma, Embryonal | 1 | 2002 | 38 | 0.050 |
Why?
|
| Myenteric Plexus | 1 | 2002 | 39 | 0.050 |
Why?
|
| Rhabdoid Tumor | 1 | 2004 | 212 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2005 | 546 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2002 | 141 | 0.050 |
Why?
|
| Crohn Disease | 2 | 2016 | 2301 | 0.050 |
Why?
|
| Smad4 Protein | 1 | 2002 | 163 | 0.050 |
Why?
|
| Desmin | 1 | 2002 | 130 | 0.050 |
Why?
|
| Cell Division | 2 | 2015 | 4564 | 0.050 |
Why?
|
| Knee | 1 | 2003 | 274 | 0.050 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2002 | 56 | 0.050 |
Why?
|
| Adenoma, Bile Duct | 1 | 2001 | 30 | 0.050 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2001 | 39 | 0.050 |
Why?
|
| Thigh | 1 | 2003 | 247 | 0.050 |
Why?
|
| Myoglobin | 1 | 2002 | 160 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2001 | 64 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2007 | 25575 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 1351 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2010 | 2504 | 0.050 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2001 | 80 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2021 | 3913 | 0.050 |
Why?
|
| Lower Extremity | 2 | 2021 | 1151 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 6483 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2003 | 594 | 0.050 |
Why?
|
| Tongue Neoplasms | 1 | 2003 | 179 | 0.050 |
Why?
|
| Dominican Republic | 1 | 2021 | 76 | 0.050 |
Why?
|
| Micromanipulation | 1 | 2001 | 53 | 0.050 |
Why?
|
| Reference Values | 2 | 1999 | 4982 | 0.050 |
Why?
|
| Betamethasone | 1 | 2021 | 45 | 0.050 |
Why?
|
| Germinoma | 1 | 2002 | 133 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2012 | 2941 | 0.050 |
Why?
|
| Endosonography | 1 | 2005 | 610 | 0.050 |
Why?
|
| DNA | 1 | 2015 | 7289 | 0.050 |
Why?
|
| Thoracic Wall | 1 | 2003 | 201 | 0.050 |
Why?
|
| Boston | 2 | 2011 | 9305 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2017 | 5975 | 0.050 |
Why?
|
| Face | 2 | 2004 | 993 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 428 | 0.050 |
Why?
|
| Metaplasia | 1 | 2001 | 313 | 0.050 |
Why?
|
| Cystadenoma, Serous | 1 | 2001 | 102 | 0.050 |
Why?
|
| Polyps | 1 | 2002 | 189 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2005 | 729 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 299 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 2274 | 0.050 |
Why?
|
| Sarcoma, Synovial | 1 | 2001 | 164 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 2003 | 370 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2010 | 6452 | 0.040 |
Why?
|
| Glucagon | 1 | 2002 | 533 | 0.040 |
Why?
|
| Cephalexin | 1 | 2019 | 37 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2021 | 374 | 0.040 |
Why?
|
| Dissection | 1 | 2001 | 294 | 0.040 |
Why?
|
| Animals | 9 | 2021 | 168561 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 2217 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 212 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2018 | 23320 | 0.040 |
Why?
|
| Facial Paralysis | 1 | 2003 | 338 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 1967 | 0.040 |
Why?
|
| Vasculitis | 1 | 2003 | 521 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 5163 | 0.040 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2017 | 828 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 800 | 0.040 |
Why?
|
| Extremities | 1 | 2004 | 865 | 0.040 |
Why?
|
| Mycobacterium chelonae | 1 | 2018 | 11 | 0.040 |
Why?
|
| Parvoviridae Infections | 1 | 1998 | 35 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 276 | 0.040 |
Why?
|
| Gastric Mucosa | 1 | 2001 | 598 | 0.040 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1998 | 97 | 0.040 |
Why?
|
| Clarithromycin | 1 | 2018 | 86 | 0.040 |
Why?
|
| Skin Absorption | 1 | 2018 | 93 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2002 | 494 | 0.040 |
Why?
|
| Arterioles | 1 | 1998 | 253 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 846 | 0.040 |
Why?
|
| Penis | 1 | 2019 | 216 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 16665 | 0.040 |
Why?
|
| Urinalysis | 1 | 2019 | 369 | 0.040 |
Why?
|
| Circumcision, Male | 1 | 2019 | 150 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2005 | 1806 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5171 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 7153 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 6313 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2017 | 1866 | 0.040 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2017 | 67 | 0.040 |
Why?
|
| United States | 3 | 2021 | 69693 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3564 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 3862 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17400 | 0.040 |
Why?
|
| Karyotyping | 1 | 1999 | 1243 | 0.040 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 195 | 0.040 |
Why?
|
| Intestinal Perforation | 1 | 1998 | 252 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 4823 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2002 | 569 | 0.040 |
Why?
|
| Elbow | 1 | 2017 | 136 | 0.040 |
Why?
|
| Phenotype | 3 | 2016 | 16331 | 0.040 |
Why?
|
| Neurilemmoma | 1 | 2002 | 547 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 1539 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2002 | 728 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2004 | 5180 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 15494 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 711 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 761 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 351 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 683 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2016 | 128 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2007 | 8436 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 72145 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 155 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2001 | 2633 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 2795 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2012 | 1847 | 0.030 |
Why?
|
| Central Nervous System Cysts | 1 | 2014 | 58 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 520 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 262 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 553 | 0.030 |
Why?
|
| Observer Variation | 1 | 2000 | 2593 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 2749 | 0.030 |
Why?
|
| Epithelium | 1 | 2019 | 1680 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2014 | 323 | 0.030 |
Why?
|
| Phylogeny | 1 | 2021 | 2797 | 0.030 |
Why?
|
| Hand | 2 | 2012 | 882 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2018 | 2335 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 2615 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 3444 | 0.030 |
Why?
|
| Recurrence | 1 | 2005 | 8333 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2012 | 6874 | 0.030 |
Why?
|
| Ligands | 1 | 2020 | 3293 | 0.030 |
Why?
|
| Incidence | 1 | 2011 | 20928 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2018 | 648 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2014 | 841 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 23387 | 0.030 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2012 | 76 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1477 | 0.030 |
Why?
|
| Mice | 5 | 2021 | 81045 | 0.030 |
Why?
|
| Peroxidases | 1 | 2012 | 138 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2002 | 1513 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 2384 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 732 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 53187 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 1107 | 0.030 |
Why?
|
| Clusterin | 1 | 2011 | 72 | 0.020 |
Why?
|
| Time Factors | 3 | 2019 | 40054 | 0.020 |
Why?
|
| Base Sequence | 2 | 2014 | 12797 | 0.020 |
Why?
|
| Brazil | 1 | 2015 | 1263 | 0.020 |
Why?
|
| Fatigue | 1 | 2018 | 1526 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2022 | 2235 | 0.020 |
Why?
|
| Triglycerides | 1 | 1998 | 2450 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 559 | 0.020 |
Why?
|
| Melanins | 1 | 2012 | 288 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2001 | 3038 | 0.020 |
Why?
|
| Alleles | 1 | 2001 | 6931 | 0.020 |
Why?
|
| Gestational Age | 1 | 1999 | 3490 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 2522 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 1670 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2014 | 895 | 0.020 |
Why?
|
| Cholesterol | 1 | 1998 | 2895 | 0.020 |
Why?
|
| Autoantigens | 1 | 2014 | 891 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2014 | 980 | 0.020 |
Why?
|
| Debridement | 1 | 2012 | 492 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2021 | 2978 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2015 | 3127 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 1093 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 3689 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2014 | 1961 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2713 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 1020 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1905 | 0.020 |
Why?
|
| Cell Separation | 1 | 2014 | 1749 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1144 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2014 | 1538 | 0.020 |
Why?
|
| Swine | 1 | 2018 | 5934 | 0.020 |
Why?
|
| Genotype | 2 | 2012 | 12946 | 0.020 |
Why?
|
| Weight Loss | 1 | 2018 | 2604 | 0.020 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2007 | 109 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2012 | 707 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 2011 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 5522 | 0.020 |
Why?
|
| Silver Compounds | 1 | 2005 | 22 | 0.020 |
Why?
|
| Homeopathy | 1 | 2005 | 25 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2014 | 2303 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 1509 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 3701 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 4414 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4249 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 21821 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9639 | 0.020 |
Why?
|
| Viscera | 1 | 2005 | 139 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 1255 | 0.020 |
Why?
|
| Leprostatic Agents | 1 | 2004 | 16 | 0.020 |
Why?
|
| Reoperation | 1 | 2014 | 4200 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2005 | 380 | 0.020 |
Why?
|
| Clofazimine | 1 | 2004 | 33 | 0.020 |
Why?
|
| West Nile virus | 1 | 2004 | 79 | 0.020 |
Why?
|
| Dapsone | 1 | 2004 | 54 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5304 | 0.020 |
Why?
|
| Pregnancy, Multiple | 1 | 2005 | 217 | 0.020 |
Why?
|
| Hemangioendothelioma | 1 | 2005 | 121 | 0.020 |
Why?
|
| Indoles | 1 | 2012 | 1834 | 0.010 |
Why?
|
| Lipids | 1 | 2015 | 3302 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 6608 | 0.010 |
Why?
|
| Apoptosis | 1 | 2020 | 9715 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 5867 | 0.010 |
Why?
|
| Sclerosis | 1 | 2004 | 210 | 0.010 |
Why?
|
| Twins | 1 | 2005 | 339 | 0.010 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2002 | 15 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2012 | 1932 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2451 | 0.010 |
Why?
|
| Forearm | 1 | 2005 | 407 | 0.010 |
Why?
|
| Cytokines | 1 | 2017 | 7317 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2018 | 7716 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2005 | 571 | 0.010 |
Why?
|
| Rifampin | 1 | 2004 | 315 | 0.010 |
Why?
|
| Foot | 1 | 2005 | 528 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2002 | 291 | 0.010 |
Why?
|
| Pruritus | 1 | 2005 | 359 | 0.010 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2002 | 153 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 13921 | 0.010 |
Why?
|
| Acute Disease | 1 | 2012 | 7141 | 0.010 |
Why?
|
| Vimentin | 1 | 2002 | 261 | 0.010 |
Why?
|
| Herpesvirus 8, Human | 1 | 2003 | 258 | 0.010 |
Why?
|
| Dermatologic Agents | 1 | 2005 | 274 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3507 | 0.010 |
Why?
|
| Pregnancy | 2 | 2017 | 29087 | 0.010 |
Why?
|
| Pneumonia, Viral | 1 | 1999 | 3236 | 0.010 |
Why?
|
| Antiporters | 1 | 2002 | 277 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 18112 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 2271 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6540 | 0.010 |
Why?
|
| Hemangioma | 1 | 2005 | 737 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2002 | 660 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3527 | 0.010 |
Why?
|
| Thalidomide | 1 | 2004 | 888 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 8925 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6259 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 9941 | 0.010 |
Why?
|
| Fibrosis | 1 | 2003 | 2026 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3839 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12220 | 0.010 |
Why?
|
| Cholangiocarcinoma | 1 | 2001 | 516 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2002 | 927 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 24913 | 0.010 |
Why?
|
| Prevalence | 1 | 2011 | 15194 | 0.010 |
Why?
|
| Adipocytes | 1 | 2001 | 1182 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 12071 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 3611 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7276 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 9581 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 35342 | 0.000 |
Why?
|
| Inflammation | 1 | 2004 | 10578 | 0.000 |
Why?
|